Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.92 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.92 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.92 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.92 |
| ▸ | FAAH | O00519 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | CNR2 | P34972 | 1/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.74 |
| ▸ | SELP | P16109 | 1/20 | 0.70 |
| ▸ | DGKA | P23743 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10452609 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL10492136 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL19564925 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL6524506 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3182554 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL1879786 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL17512151 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL16431079 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3181278 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8388194 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132906-A1 | FOCUSED ULTRASOUND THERMAL ABLATION WITH THERMAL ENHANCERS | BRACCO SUISSE SA (CH) | 2025-06-26 | — | — | WO | claimed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | claimed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1996009810-A1 | METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-04-04 | — | — | WO | claimed |
| WO-2025132906-A1 | FOCUSED ULTRASOUND THERMAL ABLATION WITH THERMAL ENHANCERS | BRACCO SUISSE SA (CH) | 2025-06-26 | — | — | WO | disclosed |
| CN-114760859-A | Dietary butyrate | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10220093-B2 | Long-acting semi-solid lipid formulations | MIRA PHARMA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180104340-A1 | LONG-ACTING SEMI-SOLID LIPID FORMULATIONS | HUZHOU HUI ZHONG JI SHI BIOTECHNOLOGY CO., LTD (CN) | 2018-04-19 | — | — | US | disclosed |
| US-9867771-B2 | Waxes derived from metathesized natural oils and amines and methods of making | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867771-B2 | Waxes derived from metathesized natural oils and amines and methods of making | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9849180-B2 | Long-acting semi-solid lipid formulations | SHEN HUI RONG (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2373295-A2 | STEROIDAL COMPOSITIONS | Lipocine Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010081032-A2 | STEROIDAL COMPOSITIONS | LIPOCINE, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1729797-A1 | ORAL PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN, CONTAINING SURFACTANTS | Solvay Pharmaceuticals GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092370-A1 | ORAL PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN, CONTAINING SURFACTANTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5750091-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5700450-A | Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5352440-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104340-A1 | LONG-ACTING SEMI-SOLID LIPID FORMULATIONS | LPXN, LIPA, CRH | PRKCA 3081/4885PRKCE 3783/4885PRKCQ 3123/4885 |
| US-10220093-B2 | Long-acting semi-solid lipid formulations | LPXN, LIPA, CRH | PRKCA 3081/4885PRKCE 3783/4885PRKCQ 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.